AU
CA
NZ
UK
US
IND
Last update at 2026-03-11T14:49:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights
Thu 08 May 25, 08:31 PMWhich stocks are moving on Monday?
Mon 07 Apr 25, 09:00 PMKeep an eye on the top gainers and losers in Monday's session.
Mon 07 Apr 25, 06:30 PMSutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights
Thu 13 Mar 25, 08:07 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -116.70400M | -105.53800M | -32.12800M | -55.74400M | -35.31700M |
| Minority interest | - | - | - | - | - |
| Net income | -119.20400M | -108.67500M | -36.20500M | -55.74400M | -35.31700M |
| Selling general administrative | 59.54M | 56.00M | 36.82M | 32.59M | 21.38M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 67.77M | 61.88M | 42.72M | 42.74M | 38.42M |
| Reconciled depreciation | 5.69M | 4.84M | 4.30M | 4.78M | 4.54M |
| Ebit | -128.94300M | -98.52400M | -71.05700M | -55.46800M | -33.69400M |
| Ebitda | -125.48800M | -93.10300M | -65.25200M | -46.61700M | -29.15500M |
| Depreciation and amortization | 3.46M | 5.42M | 5.80M | 8.85M | 4.54M |
| Non operating income net other | - | 0.58M | 1.51M | -0.27600M | 3.53M |
| Operating income | -128.94300M | -98.52400M | -71.05700M | -55.46800M | -37.22300M |
| Other operating expenses | 196.72M | 160.40M | 113.78M | 98.20M | 75.64M |
| Interest expense | 3.35M | 3.14M | 4.08M | 4.35M | 1.62M |
| Tax provision | 2.50M | - | - | - | - |
| Interest income | 3.46M | 0.58M | 1.51M | 4.07M | 1.62M |
| Net interest income | 0.11M | -2.56000M | -2.56900M | 4.07M | -0.00700M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 2.50M | 3.14M | 4.08M | 0.28M | 3.53M |
| Total revenue | 67.77M | 61.88M | 42.72M | 42.74M | 38.42M |
| Total operating expenses | 196.72M | 160.40M | 113.78M | 98.20M | 75.64M |
| Cost of revenue | - | - | - | 65.61M | 54.26M |
| Total other income expense net | 12.24M | -7.01400M | 38.93M | -0.27600M | 1.91M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -119.20400M | -105.53800M | -32.12800M | -55.74400M | -35.31700M |
| Net income applicable to common shares | -119.20400M | -105.53800M | -32.12800M | -55.74400M | -35.31700M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 470.74M | 406.94M | 341.41M | 394.11M | 156.37M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 9.85M | 11.67M | 8.12M | 4.49M | 4.41M |
| Total liab | 321.09M | 189.90M | 88.84M | 62.06M | 58.58M |
| Total stockholder equity | 149.65M | 217.05M | 252.56M | 332.05M | 97.79M |
| Deferred long term liab | - | - | - | 1.34M | 0.41M |
| Other current liab | 53.16M | -17.08500M | 14.50M | 0.63M | 6.92M |
| Common stock | 0.06M | 0.06M | 0.05M | 0.05M | 0.02M |
| Capital stock | 0.06M | 0.06M | 0.05M | 0.05M | 0.02M |
| Retained earnings | -559.40800M | -452.61500M | -333.41100M | -227.87300M | -195.74500M |
| Other liab | - | 90.00M | 0.15M | 7.92M | 16.74M |
| Good will | - | - | - | - | - |
| Other assets | - | 2.73M | 122.89M | 2.99M | 2.56M |
| Cash | 69.27M | 47.25M | 30.41M | 206.15M | 4.96M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 93.75M | 139.47M | 41.74M | 29.60M | 32.97M |
| Current deferred revenue | 20.67M | 106.64M | 5.50M | 14.60M | 19.46M |
| Net debt | 113.48M | 20.26M | 26.96M | -181.60700M | 4.92M |
| Short term debt | 10.48M | 17.09M | 10.41M | 8.82M | 1.00M |
| Short long term debt | 4.06M | 12.50M | 9.38M | - | 1.00M |
| Short long term debt total | 182.75M | 67.52M | 57.37M | 24.55M | 9.88M |
| Other stockholder equity | 708.98M | 670.22M | 586.24M | 559.75M | 293.35M |
| Property plant equipment | - | 51.06M | 51.59M | 12.94M | 9.63M |
| Total current assets | 421.54M | 309.47M | 218.51M | 378.18M | 128.57M |
| Long term investments | - | 32.02M | 68.78M | 0.00000M | 15.61M |
| Net tangible assets | - | 217.05M | 252.56M | 332.05M | 97.79M |
| Short term investments | 306.35M | 287.11M | 167.52M | 161.99M | 112.90M |
| Net receivables | 36.08M | 7.12M | 12.45M | 5.56M | 6.30M |
| Long term debt | - | 3.77M | 15.74M | 24.55M | 8.88M |
| Inventory | 0.00000M | -11.66700M | - | - | - |
| Accounts payable | 9.44M | 32.82M | 11.33M | 5.54M | 5.58M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 0.02M | -0.61800M | -0.31400M | 0.13M | 0.17M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 0.05M | 0.05M | 0.02M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | -333.41100M | -227.87300M | -195.74500M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 4.44M | 14.39M | 2.53M | 2.99M | 2.56M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 49.19M | 97.48M | 122.89M | 15.93M | 27.80M |
| Capital lease obligations | 29.57M | 34.16M | 32.26M | - | - |
| Long term debt total | - | - | 15.74M | 24.55M | 8.88M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -35.02200M | -82.00100M | 0.60M | -67.65000M | -78.71300M |
| Change to liabilities | 92.42M | -8.77400M | -15.90400M | 2.24M | 3.34M |
| Total cashflows from investing activities | -35.02200M | -97.31500M | 0.60M | -51.13100M | -80.19000M |
| Net borrowings | -9.37500M | -9.37500M | 15.00M | -5.00000M | -5.00000M |
| Total cash from financing activities | 48.31M | 3.26M | 269.25M | -4.18400M | 170.78M |
| Change to operating activities | 6.64M | -1.95100M | 3.68M | -1.52200M | 0.96M |
| Net income | -119.20400M | -105.53800M | -32.12800M | -55.74400M | -35.31700M |
| Change in cash | 16.84M | -175.73800M | 202.05M | -120.33800M | 103.28M |
| Begin period cash flow | 31.29M | 207.02M | 4.97M | 125.31M | 22.04M |
| End period cash flow | 48.13M | 31.29M | 207.02M | 4.97M | 125.31M |
| Total cash from operating activities | 3.55M | -81.67900M | -67.80200M | -65.02300M | 12.68M |
| Issuance of capital stock | 56.27M | 0.00000M | 251.41M | 0.00000M | 169.18M |
| Depreciation | 5.69M | 4.84M | 4.30M | 4.78M | 4.54M |
| Other cashflows from investing activities | 0.00900M | 0.00900M | 0.09M | 16.52M | 0.08M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | -4.54500M | -0.05800M | -1.25500M | -1.66900M |
| Change to account receivables | 5.34M | -6.89500M | 0.74M | -3.80900M | -0.86500M |
| Sale purchase of stock | 0.00000M | -0.00700M | 254.56M | 1.26M | 84.44M |
| Other cashflows from financing activities | 1.42M | 3.26M | 27.83M | 0.64M | 86.35M |
| Change to netincome | 12.66M | 36.63M | -28.48500M | 10.66M | 3.05M |
| Capital expenditures | 7.86M | 15.32M | 7.13M | 3.48M | 1.56M |
| Change receivables | - | -6.89500M | 0.74M | -3.80900M | -0.86500M |
| Cash flows other operating | - | -12.52200M | -55.58500M | -21.69400M | 38.31M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | -175.73800M | 202.05M | -120.33800M | 103.28M |
| Change in working capital | 104.41M | -17.62000M | -11.48600M | -23.26400M | 42.61M |
| Stock based compensation | 26.30M | 23.24M | 11.92M | 10.31M | 2.87M |
| Other non cash items | -13.64600M | 6.16M | 0.61M | 0.19M | -0.51700M |
| Free cash flow | -4.30900M | -97.00200M | -74.93100M | -68.50400M | 11.13M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| STRO Sutro Biopharma |
-0.28 1.10% | 25.15 | - | - | 2.07 | 2.13 | 0.03 | 0.41 |
| NVO Novo Nordisk A/S |
0.16 0.41% | 38.88 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
0.005 0.01% | 38.74 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-4.89 0.98% | 494.28 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
3.71 0.48% | 775.75 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
111 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
| Name | Title | Year Born |
|---|---|---|
| Mr. William J. Newell J.D. | CEO & Director | 1958 |
| Mr. Edward C. Albini | CFO & Sec. | 1958 |
| Dr. Trevor J. Hallam | Pres of Research & Chief Scientific Officer | 1959 |
| Ms. Jane Chung R.Ph. | Chief Commercial Officer | 1971 |
| Dr. James R. Swartz Ph.D., Sc.D. | Founder | NA |
| Dr. Shabbir T. Anik | Chief Technical Operations Officer | 1953 |
| Ms. Annie J. Chang M.B.A. | VP of Investor Relations | NA |
| Mr. David Pauling J.D., M.A. | Gen. Counsel | NA |
| Ms. Linda A. Fitzpatrick | Chief People & Communications Officer | 1957 |
| Dr. Nicki Vasquez Ph.D. | Chief Portfolio Strategy & Alliance Officer | 1963 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...